[Superficial mycoses in immunosuppressed patients].
Hernanz Hermosa
J M
JM
Servicio de Dermatología, Hospital General Universitario Gregorio Marañón, Madrid.
Lázaro Ochaita
P
P
D000328:Adult; D000935:Antifungal Agents / Q000627:therapeutic use*; D002179:Candidiasis, Cutaneous / Q000188:drug therapy; D002180:Candidiasis, Oral / Q000188:drug therapy; D002181:Candidiasis, Vulvovaginal / Q000188:drug therapy; D002648:Child; D012628:Dermatitis, Seborrheic / Q000188:drug therapy; D003881:Dermatomycoses / Q000188:drug therapy* / Q000209:etiology / Q000382:microbiology; D005260:Female; D015725:Fluconazole / Q000627:therapeutic use; D006801:Humans; D007093:Imidazoles / Q000627:therapeutic use; D007165:Immunosuppression Therapy / Q000009:adverse effects*; D017964:Itraconazole / Q000627:therapeutic use; D007654:Ketoconazole / Q000627:therapeutic use; D008297:Male; D009025:Morpholines / Q000627:therapeutic use; D014009:Onychomycosis / Q000188:drug therapy; D014005:Tinea / Q000188:drug therapy; D014010:Tinea Versicolor / Q000188:drug therapy; D014180:Transplantation; D014230:Triazoles / Q000627:therapeutic use
D000935:Antifungal Agents; D007093:Imidazoles; D009025:Morpholines; D014230:Triazoles; D017964:Itraconazole; D015725:Fluconazole; C038974:amorolfine; D007654:Ketoconazole